Clinical trials: Tuberculosis, Latent
HIV/AIDS, TB - Tuberculosis
Xpert Ultra and Xpert HIV-VL in People Living With HIV
TB is increasingly diagnosed using the GeneXpert platform, which can be used for a variety of tests (not just TB). HIV viral load monitoring is required at least annually in patients on ART to detect failure of virologic…
- Conditions
- HIV/AIDS, TB - Tuberculosis, Antiretroviral Therapy, Highly Active
- Trial name
- NCT03187964
- Testing
- PLHIV Point of Care Xpert Ultra, PLHIV Point of Care Xpert VL
- Where
- South Africa
- Volunteers
- 1,053 people
- Sponsor
- University of Stellenbosch
Active Tuberculosis, Tuberculosis, Extrapulmonary
Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
Diagnosis and treatment of tuberculosis are often delayed in hospitalized patients, leading to worse outcomes. Rapid diagnosis of tuberculosis currently relies on microscopy and molecular techniques, which have limitations…
- Conditions
- Active Tuberculosis, Tuberculosis, Extrapulmonary, Tuberculosis, Pulmonary
- Trial name
- NCT03271567
- Testing
- Nanodisk-MS assay
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Tuberculosis
Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis
This is a double-blind, masked, compared with placebo clinical trial in healthy volunteers with or without tuberculosis infection.
- Trial name
- NCT02076139
- Testing
- Nyaditum resae® 10e4, Nyaditum resae® 10e5, Distilled water
- Where
- Spain
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Manresana de Micobacteriologia, SL
TUBERCULOSIS
Clinical Evaluation of an IGRA Test for the Diagnosis of Active and Latent Tuberculosis
Methodology This is a single-center study carried out as part of routine patient care. The aim of the study is to determine the performance of the 2nd generation TB-IGRA test in the diagnosis of tuberculosis.
- Trial name
- TUBIGRA (NCT06485895)
- Testing
- test IGRA, TEST QUATIFERON TB Gold Plus
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Tuberculosis, HIV Infections
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety…
- Trial name
- NCT01404312
- Testing
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
- Where
- 45 sites in United States, Botswana and 8 more
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis Infection, Tuberculosis
Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection
The aim of the trial is to assess the safety, tolerability and immunogenicity of two doses of RUTI® vaccine administered four weeks apart after one month pre-treatment with INH.
- Trial name
- NCT01136161
- Testing
- RUTI
- Where
- 3 sites in South Africa
- Volunteers
- 95 people
- Sponsor
- Archivel Farma S.L.
Tuberculosis Infection
Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis
Tuberculosis burden in Vietnam increasing with contribution from low detection rates and increased drug resistance. There is a need to identify MDR-TB (MultiDrug Resistant Tuberculosis) among both notified TB cases and their…
- Trial name
- SNAP (NCT02175849)
- Where
- Vietnam
- Volunteers
- 596 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
HIV Seropositivity, Pregnancy
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Open-label, two-arm, randomized multicenter study to investigate the safety, tolerability, and pharmacokinetics (PK), and potential interactions between dolutegravir (DTG) and rifapentine (RPT) during pregnancy in people with HIV…
- Conditions
- HIV Seropositivity, Pregnancy, Tuberculosis Infection
- Trial name
- DOLPHIN Moms (NCT05122026)
- Testing
- Rifapentine, Isoniazid
- Where
- 3 sites in South Africa
- Volunteers
- 252 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis Infection
Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs
Tuberculosis (TB) is the world's second leading cause of death from a single infectious agent after COVID-19. In 2022, TB was estimated to have affected 10.6 million people, of whom 1.3 million died because of it, despite the…
- Trial name
- TUBILI (NCT06539455)
- Testing
- standard anti-TB treatment
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- Stefania Cheli
Tuberculosis
Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers
The purpose of this study is to access conversion rate of TST (Tuberculin skin test) and Quantiferon-TB Gold In tube assay in health care workers.
- Trial name
- NCT01376843
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Yonsei University
Latent Tuberculosis Infection
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
Successful implement of preventive therapy for subjects with latent tuberculosis infection (LTBI) is the critical step for elimination of tuberculosis (TB).
- Trial name
- NCT04094012
- Testing
- isoniazid and rifapentine
- Where
- Taiwan
- Volunteers
- 490 people
- Sponsor
- National Taiwan University Hospital
TB - Tuberculosis, Silicosis
KAP TB in Senior Management Officials of Companies With Increased Silica Exposure
The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight.
- Conditions
- TB - Tuberculosis, Silicosis, Occupational Exposure, Occupational Health
- Trial name
- KAP TB (NCT07749872)
- Where
- Zambia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Tuberculosis Infection
Equivalence Study of Specificity of PPD
Determine if investigational products and reference standard produce similar responses.
- Trial name
- 03 (NCT01798095)
- Testing
- Aplisol@ PPD material, Reference Standard
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- JHP Pharmaceuticals LLC
Tuberculosis, Latent Tuberculosis
Multi-site Cohort Study for the Development of Personalized Pharmacotherapy in Patients With Tuberculosis (TB)
Based on the collected antibiotic concentration data and individual patient's clinical information, a pharmacokinetic analysis report that can be applied for dose adjustment of the individual patient is provided.
- Conditions
- Tuberculosis, Latent Tuberculosis, Nontuberculous Mycobacterium Infection
- Trial name
- NCT05280886
- Testing
- therapeutic drug monitoring(TDM)
- Where
- 3 sites in Indonesia, South Korea
- Volunteers
- 5,000 people
- Sponsor
- Inje University
Latent Tuberculosis
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care…
- Trial name
- ASTERoiD (NCT03474029)
- Testing
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 3,400 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis, Latent Tuberculosis Infection
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
The purpose of this study is to evaluate whether isoniazid can safely (and further) reduce the risk of tuberculosis in HIV infected people receiving HAART.
- Conditions
- Tuberculosis, Latent Tuberculosis Infection, HIV Infections
- Trial name
- HAART-IPT (NCT00463086)
- Testing
- isoniazid
- Where
- South Africa
- Volunteers
- 1,368 people
- Sponsor
- University of Cape Town
Latent Tuberculosis Infection
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
A multicenter, randomized, blind, controlled trial design was used to select 240 tuberculosis (TB) patients, 120 non-tuberculous community population with other lung diseases, and 420 healthy community population without other…
- Trial name
- NCT05899179
- Testing
- Recombinant Mycobacterium Tuberculosis Fusion Protein, Purified Protein Derivative of Tuberculin
- Where
- 8 sites in China
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis
Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection
This is a doble-blind, masked, compared with placebo clinical trial in pediatric population in contact with tuberculosis with or without tuberculosis infection.
- Trial name
- NCT02581579
- Testing
- Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
- Where
- 3 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Manresana de Micobacteriologia, SL